Drug Profile
Dirocaftor - Kineta
Alternative Names: PTI-808Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Proteostasis Therapeutics
- Developer Kineta
- Class Amides; Antifibrotics; Phenols; Quinolines; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 31 Dec 2023 Nesolicaftor licensed to Fair Therapeutics
- 02 Jan 2023 No development reported - Phase-I/II for Cystic fibrosis (Combination therapy) in United Kingdom (PO)
- 02 Jan 2023 No development reported - Phase-II for Cystic fibrosis (Combination therapy) in Canada, Western Europe, New Zealand, USA (PO)